Important note

This AI stock analysis for Sangamo Therapeutics is not up to date. Creating and accessing our AI stock Analysis (powered by our data and Chat GPT) is only available for our premium users. Sign up to get access today!

Sangamo Therapeutics - AI Stock Analysis

Analysis generated September 12, 2025

Sangamo Therapeutics is a biotechnology company focused on the research, development, and commercialization of genomic therapies. The company leverages its proprietary zinc finger protein (ZFP) technology platform to address genetic diseases, offering a promising approach to gene therapy, genome editing, gene regulation, and cell therapy. Sangamo has engaged in several strategic partnerships to broaden its reach and influence in the biotech industry, collaborating with firms such as Pfizer, Biogen, and Kite Pharma.

Fundamental Analysis

Sangamo Therapeutics reported a revenue of $18 million for the last quarter, demonstrating a robust increase of 184.39% from the previous quarter. Year-over-year, this represents a staggering growth of 5,042.13%, indicating a significant leap in business activities and partnerships.

The company's net income for the last quarter was $20 million, marking an impressive rise of 34.68% compared to the previous quarter and 44.68% year-over-year. This positive income trajectory suggests effective cost management and escalating profits.

Additionally, the company’s EBITDA (earnings before interest, tax, depreciation, and amortization) for the last quarter reached $18 million, reflecting an increase of 34.80% from the previous quarter and 45.82% compared to the same quarter last year. The rise in EBITDA shows that the company is enhancing its operational efficiency and profitability.

Technical Analysis

The current stock price of Sangamo Therapeutics stands at $0.51, indicating a slight decrease of 1.92% from a month ago. Over the past year, the stock has depreciated by 40.00%, which is a cause for longer-term concern for investors.

The Simple Moving Average over 10 days (SMA10) is currently at $0.53, slightly down from the previous SMA10 of $0.54. This suggests a potential downward trend in the stock’s price, indicating bearish sentiment around the stock.

The Relative Strength Index (RSI) stands at 53.1, placing it in a neutral condition, not indicating either overbought or oversold conditions.

Alternative Data Analysis

Sangamo Therapeutics exhibits a few key indicators of growth and stability from alternative data. The number of open job positions has increased by 50% to 3 open positions, signifying potential expansion and growth. However, employee sentiment appears low, with only 34% having a positive outlook on the company's business prospects, raising some concern.

Customer acquisition metrics look positive, with an estimated 15,000 website visitors, up by 15% in recent months. This upward trend in web traffic might suggest an increasing interest from potential customers or investors. On social media platforms, Sangamo Therapeutics has 4,100 Twitter followers, with no significant change observed, indicating stable community engagement.

AltIndex’s AI score for Sangamo Therapeutics is 47, suggesting a hold signal. This score combines various fundamental, technical, and alternative data analyses to provide an overall prediction of the stock's future performance.

Conclusion and Recommendation

In conclusion, Sangamo Therapeutics exhibits strong revenue and income growth backed by increased operational efficiency. However, the technical indicators suggest a short-term bearish sentiment, with a notable decline in stock price over the past year. Alternative data presents a mixed view, with positive growth signs in job postings and web traffic, yet a low employee business outlook.

Based on the analysis of fundamental, technical, and alternative data, the recommendation is to hold the stock. The company shows promising revenue and income growth, but with some concerns around long-term stock price trends and employee sentiment. Investors may want to monitor the stock closely for any changes in these indicators before making further decisions.

Disclaimer: This AI stock analysis, generated by an experimental AI tool, is for informational purposes only and not financial advice. Information is based on publicly available data and may not always be accurate or current.